SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair (GZTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (1988)7/13/1998 2:54:00 PM
From: Machaon  Read Replies (1) of 2553
 
Linda, Epicel is an old product. It was first introduced in 1988 and is the first commercial cultured skin technology ever developed. It is now used routinely at major burn centers worldwide. This information was taken from GENZL's 1997 annual report.

So, GENZL has quite a head-start on other companies. That is why I find the reduction in growing time, from 23-24 days to 16 days important.

ORG and ATIS, are developing "generic" skin tissue. It would be interesting to see how this compares against GENZL's product. I would think that, since GENZL knows how to grow skin, and is heavily involved in Xenotransplantation, that the decision to grow skin grafts from the burn victim, instead of generic, was a strategic decision.

Good luck, Bob
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News